Literature DB >> 20400308

A convenient synthesis of (Z)-4-hydroxy-N-desmethyltamoxifen (endoxifen).

Abdul H Fauq1, Ghulam M Maharvi, Dola Sinha.   

Abstract

A mixture of the (Z)- and (E)-isomers of 4-hydroxy-N-desmethyltamoxifen was conveniently prepared in four steps. These geometrical isomers were then neatly separated by semi-preparative Reverse Phase High Performance Liquid Chromatography (RP-HPLC) using specified conditions. Additionally, the isolated E-isomer could be equilibrated in aqueous strong acid in acetonitrile or trifluoroacetic acid/dichloromethane to give a clean 1:1 mixture of Z/E isomers that was re-subjected to HPLC separation. In this way, most of the undesired (E)-isomer could be readily converted to the desired (Z)-isomer providing quick access to over 200mg quantities of pure endoxifen (Z-isomer), a potent antiestrogenic metabolite of tamoxifen traditionally used in breast cancer treatment. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400308     DOI: 10.1016/j.bmcl.2010.03.117

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis.

Authors:  Phyllis Elkins; Donna Coleman; Jason Burgess; Michael Gardner; John Hines; Brendan Scott; Michelle Kroenke; Jami Larson; Melissa Lightner; Gregory Turner; Jonathan White; Paul Liu
Journal:  J Pharm Biomed Anal       Date:  2013-07-24       Impact factor: 3.935

2.  Targeting the tamoxifen receptor within sodium channels to block osteoarthritic pain.

Authors:  Megan M McCollum; Megan Larmore; Shingo Ishihara; Leo C T Ng; Louise F Kimura; Eduardo Guadarrama; My C Ta; Thuy N Vien; Grant B Frost; Karl A Scheidt; Rachel E Miller; Paul G DeCaen
Journal:  Cell Rep       Date:  2022-08-23       Impact factor: 9.995

3.  Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.

Authors:  Patrick M Kelly; Niall O Keely; Sandra A Bright; Bassem Yassin; Gloria Ana; Darren Fayne; Daniela M Zisterer; Mary J Meegan
Journal:  Molecules       Date:  2017-08-31       Impact factor: 4.411

4.  Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.

Authors:  Wei Lv; Jinzhong Liu; Deshun Lu; David A Flockhart; Mark Cushman
Journal:  J Med Chem       Date:  2013-06-03       Impact factor: 7.446

5.  Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold.

Authors:  Niall O Keely; Miriam Carr; Bassem Yassin; Gloria Ana; David G Lloyd; Daniela Zisterer; Mary J Meegan
Journal:  Biomedicines       Date:  2016-07-20

6.  Transporting antitumor drug tamoxifen and its metabolites, 4-hydroxytamoxifen and endoxifen by chitosan nanoparticles.

Authors:  Daniel Agudelo; Sriwanna Sanyakamdhorn; Shoherh Nafisi; Heidar-Ali Tajmir-Riahi
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

7.  Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.

Authors:  Philipp Y Maximov; Daphne J Fernandes; Russell E McDaniel; Cynthia B Myers; Ramona F Curpan; V Craig Jordan
Journal:  J Med Chem       Date:  2014-05-22       Impact factor: 7.446

8.  In Vivo Performance and Properties of Tamoxifen Metabolites for CreERT2 Control.

Authors:  Anastasia Felker; Susan Nieuwenhuize; Aymeric Dolbois; Kristyna Blazkova; Christopher Hess; Larry W L Low; Sibylle Burger; Natasha Samson; Tom J Carney; Petr Bartunek; Cristina Nevado; Christian Mosimann
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.